Aim: The aim was to assess indications and clinical responses to the use of Infliximab in children with refractory inflammatory bowel disease (CD, UC, IC and others) to conventional medical treatment. Methods: We reviewed 50 case notes, median age 14.75 years (range 1.6 to 19.9 y, 28 male) in a 6 year period in our hospital. Results: The overall clinical response to Infliximab was 86% (36 patients, n = 42). Indications were Crohn's disease only (CD), response 16 out of 17 patients, fistulating CD 5/6, CD with Orofacial granulomatosis (OFG) 4/4, CD with Juvenile idiopathic arthritis (JIA) 2/2, Ulcerative colitis (UC) 4/5, Indeterminate colitis (IC) 4/5 and others 1/3. Median age at first Infliximab infusion was 13.9 y (range 1.5 to 17.10 y). Median duration of infusions was 9 months (range 1 to 33). 2 patients with UC and 2 with IC received additional Basiliximab infusions, for intractable bleeding and treatment failure. 32 patients (n = 50) had some form of immundysregulation. 38 patients (n = 46) received the standard regimen of infusions at weeks 0, 2 and 6 and then 8weekly thereafter at a dose of 5 mg/kg. All patients (n = 50) were on at least 2 immunosuppressive medications at 1st Infliximab infusion, 31 patients had 3 or more. None of the above patients had adverse reactions. Conclusion: Our findings suggest that Infliximab is an efficacious and safe treatment for intractable IBD and should be considered in patients unresponsive to conventional treatments.
Background: Acute adverse events related to infliximab infusions are challenging in the administration of this therapy. Acute reactions are not IgEmediated but the underlying mechanisms are poorly understood. The most common acute reactions, flush, urticaria, dyspnea and feverish sensation, are not always prevented by glucocorticoids. Objectives: To study if a premedication with oral antipyretic agent (paracetamol) and antihistamine (cetirizine) could decrease the frequency of acute infusion reactions. Methods: All pediatric patients scheduled for infliximab infusions at our hospital were prospectively introduced to oral paracetamol (20 mg/kg) and cetirizine (10 mg) 1h prior to infliximab infusions for one year. Acute adverse events were registered for this time period and retrospectively during the preceding year. Results: During the study period, infliximab infusions with premedication were given to 64 pediatric patients on immunosuppressants (48 with rheumatic disease and l6 with IBD; mean age 15 years). Infliximab was introduced to 14 of these children; the rest were on maintenance therapy. 12 infusion reactions, 4 mild and 8 severe, were observed in 8/64 (12.5%), in one subject four times. During the preceding year, infusion reactions occurred in 5/60 (8.3%; p > 0.05). The presentation of an acute infusion reaction was not related to the diagnosis. Conclusion: Disappointingly, in pediatric patients acute infusion reactions related to infliximab could not be prevented with premedication with oral paracetamol and cetirizine. Gastroenterology, Hepatology and Nutrition, Sheffield Children's Hospital, Sheffield, United Kingdom Case: A 16-year-old boy diagnosed with Crohn's disease presented 8 months after starting azathioprine, with fever unresponsive to broad spectrum antibiotics, lymphadenopathy and hepatosplenomegaly. His blood tests revealed pancytopenia, raised bilirubin and liver enzymes, hypoalbuminemia, deranged clotting, low fibrinogen and elevated ferritin levels. His EBV serology was positive and EBV DNA was 42,465 copies/ml. A bone marrow showed increased macrophages with evidence of haemophagocytosis. A diagnosis of haemophagocytic lymphohistiocytosis (HLH) was made and he was treated with etoposide, cyclosporine and dexamethasone (HLH4 protocol) which halted the hyperinflammatory state. His fever settled and bloods normalised. Discussion: The immunosuppressive therapy may have contributed to the development of this serious complication of EBV infection. HLH is a life threatening condition of severe hyperinflammation. Cardinal signs and symptoms include fever unresponsive to antibiotics, hepatosplenomegaly and pancytopenia. Biochemical markers include elevated triglyceride, ferritin and low fibrinogen. It can be genetic or acquired. Azathioprine is commonly used as maintenance immunosuppressive therapy in patients with inflammatory bowel disease. This unusual case highlights a potentially serious complication that patients on azathioprine therapy may be susceptible to and awareness of this condition is crucial to diagnose this condition early and start life saving treatment. Therapy with steroids can induce resistance, dependency and side effects. We demonstrated that infusions of red blood cells loaded with dexamethasone is safe and efficacious to maintain the remission in Crohn Disease (CD) patients. We continued to use this technique in the treatment of steroid dependent CD children, and extended the treatment to steroid dependent Ulcerative Colitis (UC) patients. We treated 32 patients (pts) with IBD, 22 CD and 10 UC. Mean age of patients was 14 years (range 5.4 18). Infusions have been performed every 4 weeks, mean duration of therapy has been 40 months for CD and 20 months for UC. All pts were on 5-ASA, azathioprine and steroids at the minimal efficacious dose. In CD pts mean pCDAI at the beginning was 23.8 with a decrement to 9.6 at 24 months of treatment; steroids were completely discontinued in 16 pts (73%). Three pts reduced main daily dosage of steroids, 3 didn't respond at 24 months. Evaluation up to 40 months confirmed the efficacy of the treatment in 11/19 pts (50%); 3/8 underwent surgery for stenosis. 3 pts switched on biological therapy. In steroid dependent UC the mean CAI at beginning was 6.6 and decreased to 3.6 at 20 months, but 2 pts underwent surgery and 2 dropped out. In the 6 (60%) responders CAI at 20 months was 0. No side effects have been observed in both groups of pts. RBC Dex 21P infusions is a safe therapy in steroid dependent IBD children. Efficacy of this therapy was confirmed in CD and in UC. 
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